In Massachusetts, InVivo Therapeutics Holdings Corp., a biomaterials and biomedicals company focused on spinal cord injuries, hired Christopher McNulty as CFO as of March 29th. McNulty was a former SVP of Business Development and Investor Relations at InVivo and worked directly on a follow-on offering and direct financing projects. Prior to InVivo, he worked at Repligen leading its acquisition of Novozymes Sweden, and seemingly is a jack of all trades with degrees in electrical engineering and computer science from MIT as well as an MBA from Harvard. Melanie Morel-Ferris has been serving as the interim CFO and will stay on as Senior Director of Finance and Controller.
- Advertisement -
Latest article
Sustainable surgery: Biobased caps debut at Scottish hospital
In Scotland, a hospital is helping to address medical waste by providing staff with biobased caps for the surgical theater. Made from cellulosic fiber,...
UAE expanding greenery with natural latex balloons laden with seeds
In Abu Dhabi, 100,000 natural latex balloons carrying about 100 million seeds were released on New Year’s Eve, with hopes the stunt would help...
Sequinova’s cellulose sequins help fashion stay sparkly
In London, a sustainable sequins start-up has achieved the world’s first fully biodegradable sequins produced at scale.
Founded by Claire Lichfield during the pandemic...